Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Int. j. cardiovasc. sci. (Impr.) ; 33(6): 648-655, Nov.-Dec. 2020. tab, graf
Article in English | LILACS | ID: biblio-1143105

ABSTRACT

Abstract Background The importance of regional sympathetic denervation in the pathophysiology and prognosis of Chagas disease has been recognized. Objective To conduct a review of studies that have assessed dysautonomia in chronic Chagas heart disease. Methods The search was performed on the Medline, Pubmed, Lilacs and SciELO databases. The inclusion criteria were: original articles published in full; studies on individuals with Chagas disease, that used diagnostic methods for chagasic cardiomyopathy, and had clear inclusion and exclusion criteria. Duplicate studies, studies including children (0 to 10 years old), studies involving animals, in vitro experiments, case reports, editorials, theses, and dissertations were excluded. Results A total of 281 articles were retrieved, and 10 met the inclusion criteria and were analyzed. There was great heterogeneity as to the technique for assessing dysautonomia, groups of patients studied and classification of Chagas disease. The methods used for studying the autonomic system was immunohistochemistry (n=1), Valsalva and tilt-test (n=1), scintigraphy (n=6) and Holter monitoring (n=2). The results indicated dysautonomia in the indeterminate, digestive and cardiac forms of Chagas disease, and sympathetic denervation in the indeterminate and cardiac forms of the disease. There was agreement between areas of denervation, hypoperfusion and fibrosis, but areas of denervation were larger than those of hypoperfusion. The frequency of denervation and its extension increased from the indeterminate to the cardiac form. There was an association between extension of denervation and previous history of malignant ventricular arrhythmia. Conclusions The evidence presented in this review supports that an early diagnosis of autonomic denervation in chronic Chagas' disease allows the identification of patients with an increased risk of sudden death. Int J Cardiovasc Sci. 2020; [online].ahead print, PP.0-0


Subject(s)
Chagas Cardiomyopathy/complications , Chagas Disease/diagnosis , Primary Dysautonomias/complications , Primary Dysautonomias/diagnosis , Autonomic Nervous System , Chagas Disease/mortality , Early Diagnosis
2.
Rev. Hosp. Ital. B. Aires (2004) ; 37(3): 105-111, Sept. 2017. tab.
Article in Spanish | LILACS | ID: biblio-1087981

ABSTRACT

La enfermedad con cuerpos de Lewy incluye 2 entidades que podrían ser consideradas variantes clínicas de una misma patología: la demencia con cuerpos de Lewy y la demencia en enfermedad de Parkinson. Con la finalidad de describir correctamente lo que sucede en la evolución de la enfermedad se divide el cuadro en etapa prodrómica y de demencia propiamente dicha. La primera está clínicamente representada por aquel período en el cual, si bien el paciente exhibe algunos signos y síntomas propios de la enfermedad, no reúne criterios de demencia. A pesar de ser difícil de definir y por carecerse todavía de contundentes datos clínicos y biomarcadores, se caracteriza principalmente por deterioro leve selectivo en función atencional ­ visuoespacial, trastorno del sueño REM y disautonomía‒. La segunda etapa está claramente caracterizada en los criterios de consenso del año 2005. Recientemente hemos publicado la validación de un instrumento llamado ALBA Screening Instrument, que permite diagnosticar con alta sensibilidad y especificidad la enfermedad aun en etapas tempranas y diferenciarla de otras patologías semejantes. La tomografía por emisión de positrones (PET) para transportador de dopamina es el procedimiento de referencia (gold standard) del diagnóstico. El tratamiento sintomático con anticolinesterásicos y neurolépticos atípicos favorece una buena evolución de la enfermedad y es fundamental tener en cuenta evitar medicamentos que pueden dañar gravemente a los pacientes como los anticolinérgicos y antipsicóticos típicos. Los avances en el diagnóstico y la difusión del impacto de esta enfermedad en la población contribuirán a generar mayores esfuerzos de investigación para hallar un tratamiento eficaz, preventivo o curativo o de ambas características. (AU)


Lewy body disease includes 2 entities that could be considered clinical variants of the same pathology: Dementia with Lewy bodies and Parkinson's disease Dementia. Two stages of the disease are described in this review, a prodromal stage and one of explicit dementia. The first one is clinically represented by that period in which, the patient exhibits some typical features of the disease, but not dementia criteria. Despite being difficult to define the prodromal stage and that strong clinical data and biomarkers are still lacking, there is evidence to characterize it mainly by mild selective impairment in attention and visuo-spatial function, REM sleep disorder and dysautonomia. The second stage is clearly characterized in the known consensus criteria of 2005. We have recently published the validation of an instrument called ALBA Screening Instrument which showed a high sensitivity and specificity for diagnosis of the disease even in the early stages. It´s useful to differentiate the disease from other similar pathologies. Positron Emission Tomography for dopamine transporter is the gold standard of diagnosis in life. Symptomatic treatment with anticholinesterases and atypical neuroleptics help patients in their evolution of the disease. Anticholinergics and typical antipsychotics are agents to avoid in the treatmen of the disease because can severely damage patients. Future advances in the diagnosis and dissemination of the knowledge of the disease will contribute to generate greater research efforts to find an effective preventive and / or curative treatment. (AU)


Subject(s)
Humans , Lewy Body Disease/drug therapy , Lewy Body Disease/diagnostic imaging , Parkinson Disease/pathology , Attention , Signs and Symptoms , Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Benztropine/adverse effects , Biperiden/adverse effects , Carbidopa/administration & dosage , Carbidopa/therapeutic use , Levodopa/administration & dosage , Levodopa/therapeutic use , Trihexyphenidyl/adverse effects , Cholinesterase Inhibitors/therapeutic use , Clozapine/administration & dosage , Clozapine/therapeutic use , Muscarinic Antagonists/adverse effects , Dopamine Antagonists/adverse effects , Dopamine Agonists/adverse effects , Cholinergic Antagonists/adverse effects , Risperidone/adverse effects , Lewy Body Disease/diagnosis , Lewy Body Disease/etiology , Lewy Body Disease/genetics , Lewy Body Disease/pathology , REM Sleep Behavior Disorder/complications , Dementia , Primary Dysautonomias/complications , Prodromal Symptoms , Rivastigmine/administration & dosage , Rivastigmine/therapeutic use , Quetiapine Fumarate/administration & dosage , Quetiapine Fumarate/therapeutic use , Olanzapine/adverse effects , Donepezil/administration & dosage , Donepezil/therapeutic use , Haloperidol/adverse effects , Histamine Antagonists/adverse effects , Hypnotics and Sedatives/adverse effects , Antidepressive Agents, Tricyclic/adverse effects
3.
RELAMPA, Rev. Lat.-Am. Marcapasso Arritm ; 25(4): 273-279, out.-dez. 2012. tab
Article in Spanish | LILACS | ID: lil-668985

ABSTRACT

La ludopatía fue reconocida por la Organización Mundial de la Salud en su clasificación internacional de enfermedades como una alteración progresiva del comportamiento por la cual un individuo siente una incontrolable necesidad de jugar (juegos de azar). Al igual que en otras adicciones, intervendría en el desarrollo de enfermedades cardiovasculares a través del disbalance del sistema nervioso autónomo y la predisposición a presentar arritmias.OBJETIVOS: 1) Evaluar la respuesta cardiovascular al stress simulado o provocado mediante videojuegos competitivos. 2) Prevalencia de arritmias en jugadores compulsivos. 3) Evaluar la asociación entre la presencia de arritmias y disautonomía mediante Holter. 4) Detectar asociación entre ludopatía y disautonomía.MATERIAL Y MÉTODOS: En un estudio observacional, transversal, se incluyó una población de individuos adictos al juego de cartas (n=62), varones (42) y mujeres (20) con edades comprendidas entre los 42 a 61 años (51,7 ± 9.2). Como grupo control (juego ocasional), fueron incluidas 60 personas (46 varones), edades 39 a 50 años (46.6 ± 5.1). Para ser incluidos debían ser ambulatorios sin factores de riesgo que requiriesen ningún tipo de tratamiento y firmar el consentimiento escrito. Se llevó una ficha de entrevista, hoja de orientación (diagnóstico psiquiátrico DSM IV), diagnóstico situacional (ludopatía). (South Oaks Gambling Screen SOGS) A todos ellos se les realizó examen clínico completo, análisis de laboratorio, electrocardiograma de 12 derivaciones y Holter de 24 horas. Resultados En el grupo ludópata, la alteración disautonómica fue...


Subject(s)
Humans , Male , Female , Middle Aged , Arrhythmias, Cardiac , Primary Dysautonomias/complications , Gambling/complications , Observational Studies as Topic , Risk Factors , World Health Organization
4.
Arq. bras. neurocir ; 31(2)jun. 2012. tab
Article in Portuguese | LILACS | ID: lil-666949

ABSTRACT

O termo síndrome da disautonomia pós-traumática é usado para identificar uma síndrome de hiperatividade simpática e muscular paroxística após TCE. Essa síndrome representa uma afecção grave, frequentemente subestimada na assistência ao paciente com neurotrauma e que resulta em piora da recuperação funcional e elevação dos custos hospitalares por aumento do tempo de internação. Neste artigo, realizamos uma revisão crítica da literatura sobre os princípios fisiopatológicos e abordagem terapêutica na síndrome da disautonomia no paciente com traumatismo cranioencefálico.


Dysautonomic post-traumatic syndrome consists in a paroxystic condition sympathetic and muscle hyperactivity after TBI. This syndrome is a serious condition, often underestimated in assisting the patient with neurotrauma and that result in worsening of functional recovery and increased hospital costs by increasing the length of stay. In this paper, we conducted a critical review of the literature on the physiopathological and therapeutic mechanisms in the syndrome of autonomic dysfunction in patients with traumatic brain injury.


Subject(s)
Humans , Primary Dysautonomias/complications , Primary Dysautonomias/therapy , Brain Injuries, Traumatic/complications , Brain Injuries, Traumatic/physiopathology
5.
Rev. bras. cardiol. (Impr.) ; 24(6): 377-381, nov.-dez. 2011. tab
Article in Portuguese | LILACS | ID: lil-614229

ABSTRACT

Fundamentos: Estudos demonstraram que a disfunção autonômica cardiovascular, medida através da variabilidade da frequência cardíaca, está associada a aumento do risco cardiovascular. Objetivos: Comparar a presença de disautonomia em diabéticos e não diabéticos através do teste ergométrico e determinar as variáveis preditoras de disautonomia em diabéticos. Métodos: Estudo retrospectivo, com pacientes que realizaram o teste ergométrico em caráter eletivo sob protocolo individualizado de rampa. Os pacientes foram estratificados em dois grupos: diabéticos (G1) e não diabéticos (G2). Foram definidos como disautonômicos os pacientes que obtiveram uma redução da FC no primeiro minuto da recuperação <12bpm. Os grupos G1 e G2 foram comparados. As variáveis com valores de p≤0,10 foram submetidas à análise de regressão logística. Resultados: Foram avaliados 1433 pacientes submetidos ao TE. A idade média foi 52,65±13,06 anos e variou entre 18-92 anos. Observaram-se, no G1, indivíduos mais velhos, obesos e dislipidêmicos. No teste ergométrico houve diferenças na FCR no primeiro minuto, FC do picodo esforço, número de METs e déficit cronotrópico. Submetidas as variáveis da população amostral, diabéticos e não diabéticos, à regressão logística, encontrou-se um único preditor de disautonomia: o número de METs (IC95% 0,083/0,031; p<0,0001); nos diabéticos, o único preditor independente da presença de disautonomia foi o índice de massa corporal (IC95%0,002-0,025; p=0,02). Conclusão: Indivídos diabéticos apresentam recuperação mais lenta da FC no pós-esforço que não diabéticos, evidenciando maior disautonomia e menor capacidade física; os diabéticos com excesso de peso têm maior comprometimento do sistema autonômico.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Diabetes Mellitus/diagnosis , Diabetes Mellitus/therapy , Primary Dysautonomias/complications , Primary Dysautonomias/diagnosis , Heart Rate , Exercise Test/methods , Exercise Test , Dyslipidemias/complications , Dyslipidemias/diagnosis , Obesity/complications , Risk Factors
6.
Rev. bras. cardiol. (Impr.) ; 23(4): 244-250, jul.-ago. 2010. ilus, graf
Article in Portuguese | LILACS | ID: lil-568764

ABSTRACT

O teste de esforço é um método não invasivo de grande aplicabilidade clínica na cardiologia. Seu uso, atualmente, não mais se limita ao diagnóstico de doença arterial coronariana devido à grande variedade de informações que o teste revela. A associação de alterações clínicas, hemodinâmicas e metabólicas com as alterações eletrocardiográficas ampliaram o poder não só diagnóstico, mas, especialmente o poder prognóstico do método. Mais recentemente, a avaliação do comportamento do sistema nervoso autonômico, durante o exercício dinâmico, tem mostrado grande valor em cardiopatias graves, como na insuficiência cardíaca. O objetivo desta revisão é descrever como os novos parâmetros do teste de esforço podem ser utilizados para avaliar o sistema nervoso autonômico em pacientes com insuficiência cardíaca e descrever suas implicações prognósticas.


A non-invasive method with ample clinicalapplication in cardiology, stress testing is no longer limited to diagnosing coronary artery disease, due to the broad range of information that it provides. Associating changes in clinical, metabolic and hemodynamic responses with electrocardiographic alterations has extended its diagnostic and prognosticcapacities. More recently, evaluating the behavior of the autonomic nervous system during dynamic exercise has proven extremely valuable for severecardiovascular diseases, such as heart failure. This paper describes how new stress test parameters may be deployed to evaluate the autonomic nervoussystem in heart failure patients, in addition to describing its prognostic implications.


Subject(s)
Animals , Primary Dysautonomias/complications , Primary Dysautonomias/diagnosis , Heart Failure/complications , Heart Failure/diagnosis , Exercise Test/methods , Exercise Test
SELECTION OF CITATIONS
SEARCH DETAIL